Market cap
$134 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-65 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
62,011,800
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
| 27.8 | 1.9 | 16.8 | -31.9 | -- | -- | -- |
|
BSE Sensex*
| -9.3 | -1.4 | 2.7 | -3.7 | 5.7 | 6.2 | 10.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pardes Biosciences Inc (PRDS)
|
2.2 | 134.0 | 0.0 | -96.3 | -- | -57.4 | -- | 0.4 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Pardes Biosciences Inc (PRDS)
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in... Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc. Read more
-
Founder & Director
Dr. Uri A. Lopatin M.D.
-
Founder & Director
Dr. Uri A. Lopatin M.D.
-
Headquarters
Carlsbad, CA
-
Website
FAQs for Pardes Biosciences Inc (PRDS)
What is the current share price of Pardes Biosciences Inc (PRDS) Today?
The share price of Pardes Biosciences Inc (PRDS) is $2.16 (NASDAQ) as of 08-Sep-2023 09:30 EDT. Pardes Biosciences Inc (PRDS) has given a return of -31.86% in the last 1 years.
What is the current PB & PE ratio of Pardes Biosciences Inc (PRDS)?
Since, TTM earnings of Pardes Biosciences Inc (PRDS) is negative, P/E ratio is not available.
The P/B ratio of Pardes Biosciences Inc (PRDS) is 0.37 times as on 08-Sep-2023, a 93 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-1.07 |
0.56 |
2021 |
-26.49 |
3.83 |
2020 |
-- |
-- |
2022 |
-1.07 |
0.56 |
2021 |
-26.49 |
3.83 |
What is the 52 Week High and Low of Pardes Biosciences Inc (PRDS)?
The 52-week high and low of Pardes Biosciences Inc (PRDS) are Rs -- and Rs -- as of 31-Aug-2026.
What is the market cap of Pardes Biosciences Inc (PRDS)?
Pardes Biosciences Inc (PRDS) has a market capitalisation of $ 134 Mln as on 08-Sep-2023. As per SEBI classification, it is a company.
Should I invest in Pardes Biosciences Inc (PRDS)?
Before investing in Pardes Biosciences Inc (PRDS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.